Skip to Main Content

Paper Details

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.
NPJ Breast Cancer
3
2023
Author NameAffiliation
Giuseppe CuriglianoEuropean Institute of Oncology, IRCCS
Giuseppe CuriglianoUniversity of Milano
Lajos PusztaiYale School of Medicine
  • 1 - 3

Datasets

Release 1.2